@article{Del_Vecchio_L-2023_142440,
title = {COVID-19 and cardiovascular disease: additional risks for patients with chronic kidney disease},
author = {Del Vecchio, L. and Balafa, O. and Dounousi, E. and Ekart, R. and Fernandez Fernandez, B. and Mark, P. and Sarafidis, P. and Valdivielso, J. and Ferro, C. and Mallamaci, F.},
month = {jul},
year = {2023},
abstract = {Millions of people worldwide have chronic kidney disease (CKD). Affected patients are at high risk for cardiovascular (CV) disease for several reasons. Among various comorbidities, CKD is associated with the more severe forms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This is particularly true for patients receiving dialysis or for kidney recipients. From the start of the SARS-CoV-2 pandemic, several CV complications have been observed in affected subjects, spanning acute inflammatory manifestations, CV events, thrombotic episodes and arrythmias. Several pathogenetic mechanisms have been hypothesized, including direct cytopathic viral effects on the myocardium, endothelial damage and hypercoagulability. This spectrum of disease can occur during the acute phase of the infection, but also months after recovery. This review is focussed on the CV complications of coronavirus disease 2019 (COVID-19) with particular interest in their implications for the CKD population.},
journal = {Nephrology Dialysis Transplantation},
publisher = {Oxford University Press},
url = {https://doi.org/10.1093/ndt/gfad170},
}
